Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585100 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1FFAR1CYP2C8 | |
| SCHEMBL16585271 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1FFAR1CYP2C8 | |
| SCHEMBL15938458 | 0.88 | FFAR1 (0.45) | MEN1KMT2AFFAR1ALDH1A1CYP2C19 | |
| SCHEMBL1586523 | 0.86 | MEN1 (0.52) | MEN1KMT2AMAPK1CYP2C9GAA | |
| SCHEMBL26186810 | 0.81 | FFAR1 (0.40) | MEN1KMT2AFFAR1CYP2C8CYP2C9 | |
| SCHEMBL30636963 | 0.81 | FFAR1 (0.47) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL26186802 | 0.81 | FFAR1 (0.47) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL24737344 | 0.79 | SLC9A1 (0.47) | KMT2AFFAR1CYP2C8CYP2C9ALDH1A1 | |
| SCHEMBL15542248 | 0.79 | SLC9A1 (0.47) | KMT2AFFAR1CYP2C8CYP2C9ALDH1A1 | |
| SCHEMBL29302270 | 0.79 | SLC9A1 (0.47) | KMT2AFFAR1CYP2C8CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | MEN1 4603/4885KMT2A 1209/4885MAPK1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.